Ms. Jinhua Zhang has over 20 years of experience in securities market and corporate management. Prior to founding IASO Bio, she worked in investment banks and leading securities law firms, where she led overseas and domestic listing and M&A restructuring projects for many Chinese companies. She also previously invested as an angel investor in cell therapy startups and served as director.
Drawing on her extensive background in IPOs, mergers and acquisitions and investments in the biopharmaceutical field, Ms. Zhang founded IASO Bio in March 2017 with the vision of ‘‘focusing on innovative biotherapies to bring hope of cure to patients’’. Under her leadership, IASO Bio has grown into a leader in the cell therapy sector, with end-to-end capabilities across discovery, development, manufacturing and commercialization. The company successfully launched its blockbuster CAR-T product, Fucaso in 2023.
Ms. Zhang obtained her bachelor’s degree in laws, and master’s degree in laws, both majoring in economic law, from Dongbei University of Finance and Economics.
Accolades
· Selected for the 2024 China’s New Drug Pioneer Award 20 Years 20 People
· Selected for the 2024 Fortune China’s Most Powerful Women in Business Future List
Dr. Yongke Zhang serves as the Chief Scientific Officer and Senior Vice President at IASO Bio. He has over 26 years of experience in the industry.
Dr. Yongke Zhang's career began at Merck Research Labs (previously known as DNAX Research Institute) in the USA, where he worked as a Scientist, primarily responsible for developing cell cycle inhibitors for malignant tumors. He subsequently joined AbbVie (previously known as PDL Biopharma Inc.) in the USA, where he was primarily responsible for developing antibody humanization technology and therapeutic antibody. Thereafter, he worked at Epitomics in the USA, focusing on the development of therapeutic rabbit monoclonal antibody pipelines. He then joined Apexigen in the USA as Director of Preclinical Development and Clinical Research, responsible for the company's R&D and the management of early-stage clinical trials. Later, he served as Chief Executive Officer of AbCyte Therapeutics in the USA, leading the development of therapeutic antibodies and CAR-T cell therapies. Most recently, he held the position of Vice President at OBiO Tech in the USA, where he was primarily responsible for business development related to overseas outsourcing of cell and gene therapy processes.
Dr.Zhang obtained his doctor's degree in Internal Medicine, Clinical Medicine, from Health Science Center of Peking University (previously known as Beijing Medical University). He further obtained his doctor's degree in Cell and Molecular Biology from the University of Tokyo in Japan.
Mr. Hua Zhang serves as our Chief Commercial Officer and Senior Vice President. Mr. Zhang has over 24 years of experience in marketing and business promotion.
He began his career as a Regional Manager, Sales Director and Senior Marketing Manager at Pfizer in Shanghai, where he was primarily responsible for formulating marketing strategy and managing sales. Then, he worked as a Marketing Director of Northern China at Merck Serono in Beijing, where he was primarily responsible for formulating marketing strategy and managing the operations of the marketing department. After that, he served as a Marketing Director of Southern China at Bayer Healthcare (Shanghai), where he was primarily responsible for formulating marketing strategies. Later, he successively served as a Business Operations Manager and a Deputy Chief Commercial Officer at Fosun Kairos (Shanghai) (previously known as Fosun Kite), where he was primarily responsible for assisting in strategic decision-making.
Mr. Zhang obtained his bachelor's degree in pharmacology from Shanghai Medical College of Fudan University (previously known as Shanghai Medical University). He further obtained his master's degree in business administration from Fudan University in Shanghai. He has been qualified as a licensed pharmacist by the National Medical Products Administration and the Ministry of Human Resources and Social Security.
Dr. Jie Chen serves as our Chief Medical Officer and Senior Vice President. Dr. Chen has over 39 years of experience in the medical industry.
Dr. Chen started his career as a resident doctor at a military unit. Then, he successively worked as Attending Physician, Lecturer, Deputy Chief Physician and Associate Professor at Xinqiao Hospital Affiliated to the Third Military Medical University, where he was primarily responsible for clinical medical care, teaching and scientific research work. After that, he worked as a Medical Director at Pfizer, where he was primarily responsible for coordinating clinical strategies. Later, he worked at Bristol Myers Squibb (Shanghai) as a Senior Medical Director, where he was primarily responsible for new product launch and product lifecycle management. Then, he served as Vice President and the Head of Medical Affairs at Takeda (China), where he was primarily responsible for new product launch and product lifecycle management. Mostly recently, he served as Chief Medical Officer at Nanjing Bioheng Biotech, where he was primarily responsible for developing clinical development strategies and implementing clinical development plans.
Dr.Chen obtained his bachelor's degree in Clinical Medicine, master's degree in Clinical Medicine and doctor's degree in Medicine from Third Military Medical University.
